Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01710852 | Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation | PHASE2 | COMPLETED | 7 | — | — | Oct 1, 2012 | Apr 1, 2014 | Aug 26, 2015 | 1 | United Kingdom |
Burden measured as percentage of time spent in AF as derived from continuous pacemaker monitoring
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | ISIS CRP Rx followed by Placebo |
| Group B | EXPERIMENTAL | Placebo followed by ISIS CRP Rx |
| Name | Type | Description |
|---|---|---|
| ISIS CRP Rx | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Male of female; age over 18 years * Dual chamber permanent pacemaker implanted * Confirmed diagnosis of paroxysmal atrial fibrillation with an AF burden of 1 to 50%, as derived from pacemaker diagnostic algorithms * Able to have pacemaker antiarrhythmic algorithms turned off f...